In this report, in the last several years, global market of testosterone replacement therapy developed slowly, with an average growth rate of 2.11%. In 2016, global revenue of testosterone replacement therapy was nearly 1.92 billion M USD; the production was about 54.8 million units.
Testosterone deficiency, also referred to as hypogonadism, is a common problem among men aged between 40 and 79 years, with some studies stating that nearly 30% of all men worldwide are affected by hypogonadism. As the incidence of testosterone deficiency increases, it is expected that the demand for TRT will also show a simultaneous increase.
The classification of testosterone replacement therapy includes gels, injections, patches and other types, and the proportion of gels in 2016 was about 72%.
Testosterone replacement therapy is widely sold in hospitals, clinics and other field. The most proportion of testosterone replacement therapy was sold in clinics, and the consumption proportion was about 43%.
North America region was the largest supplier of testosterone replacement therapy, with a production market share nearly 86% in 2016. Europe was the second largest supplier of Testosterone Replacement Therapy, enjoying production market share nearly 9.9% in 2016.
Market competition is intense. AbbVie, Endo International, Eli Lilly, Pfizer, Actavis (Allergan)
Bayer, etc. are the leaders of the industry. The top five players together held about 80% of the market in the same year and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
Geographically, this report split global into several key Regions, with sales (K Units), revenue (M USD), market share and growth rate of Testosterone Replacement Therapy for these regions, from 2014 to 2026 (forecast), covering
China
USA
Europe
Japan
Korea
India
Southeast Asia
South America
Global Testosterone Replacement Therapy market competition by top manufacturers/players, with Testosterone Replacement Therapy sales volume, Price (USD/Unit), revenue (M USD) and market share for each manufacturer/player; the top players including
AbbVie
Endo International
Eli lilly
Pfizer
Actavis (Allergan)
Bayer
Novartis
Teva
Mylan
Upsher-Smith
Ferring Pharmaceuticals
Kyowa Kirin
Acerus Pharmaceuticals
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
Gels
Injections
Patches
Other
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Testosterone Replacement Therapy for each application, including
Hospitals
Clinics
Others
If you have any special requirements, please let us know and we will offer you the report as you want.
Summary:
Get latest Market Research Reports on Testosterone Replacement Therapy Sales. Industry analysis & Market Report on Testosterone Replacement Therapy Sales is a syndicated market report, published as Global Testosterone Replacement Therapy Sales Market(Sales,Revenue and competitors Analysis of Major Market)from 2014-2026. It is complete Research Study and Industry Analysis of Testosterone Replacement Therapy Sales market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.